

**Table 13.6g**  
**Immunosuppression Use for Maintenance Between Discharge**  
**and One Year Following Transplantation, 1997 to 2006**  
**Recipients with Heart-Lung Transplants**

	Year of Transplant									
	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
<b>Transplants</b>	62	47	51	48	27	33	29	40	35	31
<b>Tx with Follow-up Immunosuppression Info</b>	34	24	28	29	21	21	13	30	26	20
<b>Corticosteroids</b>										
Any in Category	100.0%	95.8%	96.4%	100.0%	95.2%	100.0%	92.3%	100.0%	100.0%	100.0%
Steroids	100.0%	95.8%	96.4%	100.0%	95.2%	100.0%	92.3%	100.0%	100.0%	100.0%
<b>Cyclosporine</b>										
Any in Category	55.9%	62.5%	53.6%	58.6%	47.6%	52.4%	38.5%	36.7%	50.0%	15.0%
Sandimmune	5.9%	0.0%	0.0%	6.9%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Neoral	50.0%	62.5%	53.6%	44.8%	42.9%	47.6%	23.1%	26.7%	30.8%	5.0%
Gengraf	0.0%	0.0%	0.0%	6.9%	4.8%	4.8%	15.4%	10.0%	19.2%	10.0%
Eon	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
<b>Tacrolimus</b>										
Any in Category	47.1%	37.5%	50.0%	58.6%	76.2%	66.7%	76.9%	73.3%	84.6%	90.0%
Tacrolimus	47.1%	37.5%	50.0%	58.6%	76.2%	66.7%	76.9%	73.3%	84.6%	90.0%
<b>Antimetabolites</b>										
Any in Category	88.2%	95.8%	89.3%	93.1%	95.2%	95.2%	84.6%	90.0%	100.0%	100.0%
Mycophenolate Mofetil	23.5%	54.2%	42.9%	48.3%	47.6%	38.1%	38.5%	43.3%	53.8%	60.0%
Mycophenolate Sodium	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Azathioprine	64.7%	41.7%	46.4%	44.8%	47.6%	57.1%	46.2%	46.7%	46.2%	40.0%
Cytosan	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
<b>mTOR Inhibitors</b>										
Any in Category	0.0%	4.2%	3.6%	10.3%	0.0%	9.5%	0.0%	6.7%	7.7%	0.0%
Sirolimus	0.0%	4.2%	3.6%	10.3%	0.0%	9.5%	0.0%	6.7%	7.7%	0.0%
Everolimus	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 1, 2008.

Notes:

Percentages are calculated based on the total number of patients with any immunosuppression use between discharge and one year following transplantation.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.